SE465676B - Flavolignanderivat, saett att framstaella detta och ett farmaceutiskt medel - Google Patents

Flavolignanderivat, saett att framstaella detta och ett farmaceutiskt medel

Info

Publication number
SE465676B
SE465676B SE8505487A SE8505487A SE465676B SE 465676 B SE465676 B SE 465676B SE 8505487 A SE8505487 A SE 8505487A SE 8505487 A SE8505487 A SE 8505487A SE 465676 B SE465676 B SE 465676B
Authority
SE
Sweden
Prior art keywords
silibinin
ethyl acetate
animals
burns
derivatives
Prior art date
Application number
SE8505487A
Other languages
English (en)
Swedish (sv)
Other versions
SE8505487D0 (sv
SE8505487L (sv
Inventor
R Braatz
K Goerler
G Halbach
H Soicke
K Schmidt
Original Assignee
Madaus Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madaus Ag filed Critical Madaus Ag
Publication of SE8505487D0 publication Critical patent/SE8505487D0/xx
Publication of SE8505487L publication Critical patent/SE8505487L/xx
Publication of SE465676B publication Critical patent/SE465676B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Silicon Compounds (AREA)
SE8505487A 1984-11-22 1985-11-20 Flavolignanderivat, saett att framstaella detta och ett farmaceutiskt medel SE465676B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19843442639 DE3442639A1 (de) 1984-11-22 1984-11-22 Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten

Publications (3)

Publication Number Publication Date
SE8505487D0 SE8505487D0 (sv) 1985-11-20
SE8505487L SE8505487L (sv) 1986-05-23
SE465676B true SE465676B (sv) 1991-10-14

Family

ID=6250903

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8505487A SE465676B (sv) 1984-11-22 1985-11-20 Flavolignanderivat, saett att framstaella detta och ett farmaceutiskt medel

Country Status (29)

Country Link
JP (1) JPS61143377A (OSRAM)
KR (1) KR870001020B1 (OSRAM)
AR (1) AR240931A1 (OSRAM)
AT (1) AT393268B (OSRAM)
BE (1) BE903693A (OSRAM)
CA (1) CA1337124C (OSRAM)
CH (1) CH659473A5 (OSRAM)
CS (1) CS273610B2 (OSRAM)
DD (1) DD259191A1 (OSRAM)
DE (1) DE3442639A1 (OSRAM)
DK (1) DK164865C (OSRAM)
EG (1) EG19424A (OSRAM)
ES (1) ES8609311A1 (OSRAM)
FI (1) FI84064C (OSRAM)
FR (1) FR2573427B1 (OSRAM)
GB (1) GB2167414B (OSRAM)
HU (1) HU195503B (OSRAM)
IE (1) IE58791B1 (OSRAM)
IT (1) IT1190426B (OSRAM)
LU (1) LU86163A1 (OSRAM)
MX (1) MX168415B (OSRAM)
NL (1) NL192387C (OSRAM)
NO (1) NO160205C (OSRAM)
PL (1) PL146890B1 (OSRAM)
PT (1) PT81532B (OSRAM)
SE (1) SE465676B (OSRAM)
SU (1) SU1436875A3 (OSRAM)
YU (1) YU43689B (OSRAM)
ZA (1) ZA858951B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8716918D0 (en) * 1987-07-17 1987-08-26 Inverni Della Beffa Spa Soluble derivatives of silybin
US5262439A (en) * 1992-04-30 1993-11-16 The Regents Of The University Of California Soluble analogs of probucol
SG162773A1 (en) * 2005-03-11 2010-07-29 Florey Howard Inst Flavonoid compounds and uses thereof
AU2008323156B2 (en) * 2007-11-15 2012-05-31 Madaus Gmbh Silibinin component for the treatment of hepatitis
RU2482844C2 (ru) * 2007-11-15 2013-05-27 Мадаус Гмбх Силибининовый компонент для лечения гепатита
CA2761656C (en) * 2009-05-14 2017-02-07 Lucio Claudio Rovati Amorphous silibinin for the treatment of viral hepatitis
CA2877338C (en) 2012-07-05 2022-10-11 Nutramax Laboratories, Inc. Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
CN103113359B (zh) * 2013-02-22 2016-01-06 西安安健药业有限公司 水飞蓟宾二偏琥珀酸酯及其药用盐
CN103193768B (zh) * 2013-02-22 2016-03-30 西安安健药业有限公司 治疗肝病的水飞蓟宾二偏琥珀酸酯异构体
CN103172622B (zh) * 2013-02-22 2015-11-04 西安安健药业有限公司 水飞蓟宾二偏琥珀酸酯的活性异构体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963318A1 (de) * 1969-12-17 1971-06-24 Schwabe Willmar Gmbh & Co Silybinhalbester der Bernsteinsaeure und der Phthalsaeure,ihre Salze mit pharmakologisch vertraglichen Basen,Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneipraeparaten

Also Published As

Publication number Publication date
AR240931A1 (es) 1991-03-27
FI84064B (fi) 1991-06-28
JPS61143377A (ja) 1986-07-01
EG19424A (en) 1995-02-28
FR2573427A1 (fr) 1986-05-23
GB8528226D0 (en) 1985-12-18
IE58791B1 (en) 1993-11-17
NO160205C (no) 1989-03-22
SU1436875A3 (ru) 1988-11-07
DK164865B (da) 1992-08-31
HUT40114A (en) 1986-11-28
SE8505487D0 (sv) 1985-11-20
FI84064C (fi) 1991-10-10
MX168415B (es) 1993-05-24
ZA858951B (en) 1986-08-27
GB2167414B (en) 1989-01-11
SE8505487L (sv) 1986-05-23
YU43689B (en) 1989-10-31
PT81532B (pt) 1987-11-11
NO160205B (no) 1988-12-12
ES8609311A1 (es) 1986-09-01
NL192387C (nl) 1997-07-04
CA1337124C (en) 1995-09-26
NL192387B (nl) 1997-03-03
YU178685A (en) 1988-02-29
PL146890B1 (en) 1989-03-31
LU86163A1 (de) 1986-03-24
AT393268B (de) 1991-09-25
FI854535A7 (fi) 1986-05-23
DK164865C (da) 1993-01-18
GB2167414A (en) 1986-05-29
DK537785D0 (da) 1985-11-21
DE3442639A1 (de) 1986-05-22
FR2573427B1 (fr) 1989-03-10
NL8503171A (nl) 1986-06-16
HU195503B (en) 1988-05-30
DK537785A (da) 1986-05-23
KR870001020B1 (ko) 1987-05-23
JPH0432073B2 (OSRAM) 1992-05-28
IT1190426B (it) 1988-02-16
BE903693A (fr) 1986-05-22
CS837885A2 (en) 1990-08-14
IE852808L (en) 1986-05-22
IT8522932A0 (it) 1985-11-21
DE3442639C2 (OSRAM) 1989-08-10
CS273610B2 (en) 1991-03-12
KR860004056A (ko) 1986-06-16
ATA337185A (de) 1991-02-15
CH659473A5 (de) 1987-01-30
NO854655L (no) 1986-05-23
FI854535A0 (fi) 1985-11-18
AR240931A2 (es) 1991-03-27
PT81532A (de) 1985-12-01
PL256374A1 (en) 1986-12-02
ES549116A0 (es) 1986-09-01
DD259191A1 (de) 1988-08-17

Similar Documents

Publication Publication Date Title
DE69332220T2 (de) Lösliche analoga von probucol
US4764508A (en) Complexes of flavanolignans with phospholipids, preparation thereof and associated pharmaceutical compositions
KR0134376B1 (ko) 면역 억제제로서 유용한 4-퀴놀린 카르복실산 유도체
SE465676B (sv) Flavolignanderivat, saett att framstaella detta och ett farmaceutiskt medel
NO160206B (no) Fremgangsmaate ved fremstilling av isosilybinfri silibinin.
JP3075358B2 (ja) 肝機能改善剤
US4448788A (en) 11-Deoxoglycyrrhetinic acid hydrogen maleate, process for its production, and its use as a medicine
EP1140115B1 (en) Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
JPH10218769A (ja) 抗潰瘍剤
JP3110500B2 (ja) 血糖上昇抑制剤
JP3243879B2 (ja) 抗高脂血症剤
FR2526792A1 (fr) Derives d'aletheine utiles pour le traitement des lesions hepatiques
US3463861A (en) Compositions and method of treating mycobacterium tuberculosis with 2,2'-(ethylenediimino)-di-1-butanols
EP0121856A2 (de) Verwendung von Pyrazolonderivaten bei der Bekämpfung des Wachstums von Tumorzellen und der Metastasenbildung, Arzneimittel hierfür und Verfahren zu deren Herstellung
US4883813A (en) Method of treating inflammation in mammals utilizing ketobutyrolactones and furylbutyrolactones
AU2001242730B2 (en) An Anti-Diabetic Agent obtained from the plant Humboldtia Decurrens and a Process for preparing the same
JPH06340646A (ja) プロスタグランジン誘導体
JPH0220612B2 (OSRAM)
FR2526789A2 (fr) Nouveaux derives d'acides phenyl aliphatique carboxyliques, procede pour leur preparation et leur application comme medicaments
AU2001242730A1 (en) An Anti-Diabetic Agent obtained from the plant Humboldtia Decurrens and a Process for preparing the same

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8505487-2

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8505487-2

Format of ref document f/p: F